Real-world Aliskiren Use in Diabetic Patients

Novartis200 enrolled

Overview

The purpose of this study is to evaluate real-world patterns of aliskiren use with a focus of change in renal function following aliskiren initiation as well as to identify "triggering events" that lead to aliskiren initiation.

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Diabetes Hypertension

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Type 2 diabetes * Patients ages 18 yeras and older * Hypertension Diagnosis * Currently on at least 1 hypertensive medication * At least 2 lab measure before and after aliskiren initiation Exclusion Criteria: * Inadequate chart records where microalbuminuria, serum creatinine and blood pressure data are not within 3-12 months prior to initiation of Aliskiren * Pregnancy * Development of secondary renal disease unrelated to diabetes (such as nephritis) * Terminal illness * AIDS/HIV Other protocol-defined inclusion/exclusion criteria may apply

Locations (1)

MODEL Clinical Research, Research Division of Bay Endocrinology Associates GBMC Physicians pavilion North

Baltimore, Maryland, United States

Outcomes

Primary Outcomes

Measure: Change in blood pressure

Time frame: baseline and 1 year

Secondary Outcomes

Measure: Change in urine microalbumin

Time frame: baseline and 1 year

Measure: Change in creatinine

Time frame: baseline and 1 year

Measure: Change in potassium levels

Time frame: baseline and 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.